CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This activity has been designed to meet the educational needs of medical oncologists, hematologists, hematology-oncology fellows, nurse practitioners, clinical nurse specialists and other allied cancer professionals involved in the treatment of cancer.
  
  LEARNING OBJECTIVES

  • Effectively apply the results of practice-changing clinical research to the care of patients with breast cancer, gastrointestinal cancers, genitourinary cancers, gynecologic cancers, lung cancer, melanoma and select hematologic cancers
  • Appraise the clinical relevance of recent pivotal cancer research published in peer-reviewed journals or presented at major oncology conferences.
  • Recall ongoing clinical trials in breast cancer, gastrointestinal cancers, genitourinary cancers, gynecologic cancers, lung cancer, melanoma and select hematologic cancers, and refer appropriate patients for participation.
  • Incorporate clinical characteristics, logistical factors, tumor biomarkers and single and multigene signatures in individualizing therapy for patients with cancer. 
  • Educate patients with hematologic cancers and solid tumors about the benefits and risks of new therapeutic agents and strategies.
  • Refine or validate existing cancer treatment algorithms, considering new data sets and the perspectives of tumor-specific clinical investigators.
  • Evaluate the mechanisms of action, tolerability and efficacy of promising investigational agents, and consider the implications for clinical practice.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  CME credit is no longer available for this issue
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  CME credit is no longer available for this issue
  
  HOW TO USE THIS CME ACTIVITY
  Audio Program: This CME activity consists of an audio component.
  CME credit is no longer available for this issue
  
  Video Program: This CME activity consists of a video component.
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
  
  Ghassan Abou-Alfa, MD, MBA
  Attending
  Memorial Sloan Kettering Cancer Center
  Professor
  Weill Cornell Medical College at Cornell University
  New York, New York
  
  Consulting Agreements: Adicet Bio, Alnylam Pharmaceuticals Inc, AstraZeneca Pharmaceuticals LP, Autem Medical, BeiGene Ltd, Berry Genomics, Boehringer Ingelheim Pharmaceuticals Inc, Celgene Corporation, Cend Therapeutics, CytomX Therapeutics, Eisai Inc, Exelixis Inc, Flatiron Health, Genentech, a member of the Roche Group, Genoscience Pharma, Helio Health, Helsinn Healthcare SA, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Lilly, Merck, Nerviano Medical Sciences, NewBridge Pharmaceuticals, Novartis, QED Therapeutics, Rafael Pharmaceuticals Inc, RedHill Biopharma Ltd, Servier Pharmaceuticals LLC, Silenseed Ltd, Sobi, Vector Pharma, Yiviva; Contracted Research: Arcus Biosciences, AstraZeneca Pharmaceuticals LP, BioNTech, Bristol Myers Squibb, Celgene Corporation, Flatiron Health, Genentech, a member of the Roche Group, Genoscience Pharma, Incyte Corporation, Polaris Group, Puma Biotechnology Inc, QED Therapeutics, Silenseed Ltd, Yiviva.>
  
  Matthew P Goetz, MD
  Erivan K Haub Family Professor of Cancer Research Honoring Richard F Emslander, MD
  Professor of Oncology and Pharmacology
  Enterprise Deputy Director, Translational Research
  Director, Mayo Clinic Breast Cancer SPORE
  Mayo Clinic
  Rochester, Minnesota
  
  Advisory Committee: ARC Therapeutics, bioTheranostics Inc, Blueprint Medicines, Sanofi; Consulting Agreements: AstraZeneca Pharmaceuticals LP, Biovica, Context Therapeutics, Eagle Pharmaceuticals, Lilly, Novartis, Pfizer Inc; Contracted Research: Lilly, Pfizer Inc, Sermonix Pharmaceuticals; Nonrelevant Financial Relationship (CME Presentation Fees): Clinical Education Alliance, Medscape, MJH Life Sciences; Nonrelevant Financial Relationship (Panelist): Total Health Conferencing.
  
  Ian E Krop, MD, PhD
  Associate Director, Clinical Research
  Director, Clinical Trials Office
  Chief Clinical Research Officer
  Yale Cancer Center
  New Haven, Connecticut
  
  Consulting Agreements: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, MacroGenics Inc, Seagen Inc; Contracted Research: Genentech, a member of the Roche Group, MacroGenics Inc, Pfizer Inc; Data and Safety Monitoring Board/Committee: Merck, Novartis.
  
  Ann S LaCasce, MD, MMSc
  Director, Dana-Farber/Mass General Brigham Fellowship in Hematology/Oncology
  Associate Professor of Medicine, Harvard Medical School
  Lymphoma Program
  Dana-Farber Cancer Institute
  Boston, Massachusetts
  
  Advisory Committee: Seagen Inc.
  
  Corey J Langer, MD
  Director of Thoracic Oncology
  Abramson Cancer Center
  Professor of Medicine
  Perelman School of Medicine
  University of Pennsylvania
  Philadelphia, Pennsylvania
  
  Advisory Committee: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Guardant Health, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Merck, Novocure Inc, Regeneron Pharmaceuticals Inc; Consulting Agreements: Amgen Inc, Janssen Biotech Inc, Merck, Regeneron Pharmaceuticals Inc, Sanofi; Contracted Research: Amgen Inc, Candel Therapeutics, Cantargia AB, FUJIFILM Pharmaceuticals USA Inc, Heat Biologics, Inovio Pharmaceuticals Inc, Merck, Trizell; Nonrelevant Financial Relationship: US Department of Veterans Affairs (VALOR trial DSMB).
  
  Prof Georgina Long, AO, BSc, PhD, MBBS
  Co-Medical Director
  Professor of Medical Oncology and Translational Research
  Melanoma Institute Australia
  Wollstonecraft, New South Wales, Australia
  
  Consulting Agreements: Agenus Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Evaxion Biotech A/S, Hexal AG, Highlight Therapeutics SL, Innovent USA, Merck Sharp & Dohme LLC, Novartis, OncoSec Medical, PHMR, Pierre Fabre, Provectus Biopharmaceuticals Inc, QBiotics, Regeneron Pharmaceuticals Inc.
  
  Christine M Lovly, MD, PhD
  Associate Professor of Medicine, Division of Hematology and Oncology
  Ingram Associate Professor of Cancer Research
  Co-Leader, Translational Research and Interventional Oncology Program
  Vanderbilt University Medical Center and Vanderbilt-Ingram Cancer Center
  Nashville, Tennessee
  
  Advisory Committee and Consulting Agreements: Amgen Inc, ArriVent Biopharma, AstraZeneca Pharmaceuticals LP, Blueprint Medicines, Cepheid, D2G Oncology Inc, Daiichi Sankyo Inc, EMD Serono Inc, Foundation Medicine, Genentech, a member of the Roche Group, Janssen Biotech Inc, Lilly, Novartis, Pfizer Inc, Puma Biotechnology Inc, Roche Laboratories Inc, Syros Pharmaceuticals Inc, Takeda Pharmaceuticals USA Inc; Data and Safety Monitoring Board/Committee: Janssen Biotech Inc (uncompensated); Nonrelevant Financial Relationship: Medscape.
  
  Wells A Messersmith, MD
  Chief Medical Officer, Cancer Center
  Associate Director of Clinical Services
  University of Colorado Cancer Center
  Aurora, Colorado
  
  Consulting Agreements: Cardiff Oncology, Istari Oncology; Contracted Research: ALX Oncology, AStar EDCC, BeiGene Ltd, CanBas Co Ltd, Exelixis Inc, Fate Therapeutics, Pfizer Inc, PureTech Health, Mirati Therapeutics, Rascal Therapeutics; Data and Safety Monitoring Board/Committee: Amgen Inc, QED Therapeutics, Zymeworks Inc; Unpaid Advisory Board: Pfizer Inc, Takeda Pharmaceuticals USA Inc; Nonrelevant Financial Relationship: Criterium.
  
  Alicia K Morgans, MD, MPH
  Genitourinary Medical Oncologist
  Medical Director, Survivorship Program
  Dana-Farber Cancer Institute
  Boston, Massachusetts
  
  Advisory Committee: Bayer HealthCare Pharmaceuticals, Gilead Sciences Inc, MyovantSciences; Consulting Agreements: Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Exelixis Inc, Janssen Biotech Inc, Lantheus, Merck, Myovant Sciences, Novartis, Pfizer Inc, Sanofi, Telix Pharmaceuticals; Contracted Research: Astellas, Bayer HealthCare Pharmaceuticals, Dendreon Pharmaceuticals Inc, Myovant Sciences, Pfizer Inc, Seagen Inc; Data and Safety Monitoring Board/Committee: Gilead Sciences Inc.
  
  David M O'Malley, MD
  Professor
  Division Director, Gynecologic Oncology
  The Ohio State University and The James Cancer Center
  Columbus, Ohio
  
  Funding for Clinical Research: AbbVie Inc, Agenus Inc, Ajinomoto Co Inc,Amgen Inc, ArrayBioPharma Inc, a subsidiary of Pfizer Inc, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Clovis Oncology, Daré Bioscience, Eisai Inc, EMD Serono Inc, Ergomed Plc, Genentech, a member of the Roche Group, Genmab, ImmunoGen Inc, Iovance Biotherapeutics, Janssen Biotech Inc, Johnson & Johnson Pharmaceuticals, Merck, Merck Serono, Mersana Therapeutics Inc, New Mexico Cancer Care Alliance, Novocure Inc, PRA Health Sciences, Regeneron Pharmaceuticals Inc, Seagen Inc, Stemcentrx, Sumitomo Dainippon Pharma Oncology Inc, Syneos Health, Tesaro, A GSK Company, TRACON Pharmaceuticals Inc, VentiRx Pharmaceuticals Inc; Personal Fees (Consulting and/or Advisory Boards): AbbVie Inc, Ambry Genetics, Amgen Inc, Arquer Diagnostics, AstraZeneca Pharmaceuticals LP, Celsion Corporation, Clovis Oncology, Corcept Therapeutics, Eisai Inc, Elevar Therapeutics, Genentech, a member of the Roche Group, ImmunoGen Inc, InxMed, Iovance Biotherapeutics, Janssen Biotech Inc, Johnson & Johnson Pharmaceuticals, Merck, Mersana Therapeutics Inc, Novartis, Novocure Inc, Regeneron Pharmaceuticals Inc, Roche Diagnostics MSA, Seagen Inc, Sorrento Therapeutics, Sumitomo Dainippon Pharma Oncology Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, Toray; Personal Fees: Agenus Inc, Myriad Genetic Laboratories Inc, Rubis, Tarveda Therapeutics; Nonrelevant Financial Relationship: GOG Foundation Inc, Ludwig Institute for Cancer Research Ltd, Yale University.
  
  Thomas Powles, MBBS, MRCP, MD
  Professor of Genitourinary Oncology
  Barts Cancer Institute
  Director of Barts Cancer Centre
  Queen Mary University of London
  London, United Kingdom
  
  Consulting Agreements: Astellas, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Eisai Inc, Exelixis Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Johnson & Johnson Pharmaceuticals, Merck Serono, Merck Sharp & Dohme LLC, Novartis, Pfizer Inc, Roche Laboratories Inc, Seagen Inc; Contracted Research: Astellas, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Eisai Inc, Exelixis Inc, Ipsen Biopharmaceuticals Inc, Johnson & Johnson Pharmaceuticals, Merck Serono, Merck Sharp & Dohme LLC, Novartis, Pfizer Inc, Roche Laboratories Inc, Seagen Inc; Travel/Accommodation/Expenses: AstraZeneca Pharmaceuticals LP, Ipsen Biopharmaceuticals Inc, Merck Sharp & Dohme LLC, Pfizer Inc, Roche Laboratories Inc; Nonrelevant Financial Relationship: Mashup Media LLC.
  
  Mitchell R Smith, MD, PhD
  Clinical Professor of Medicine
  George Washington University
  Washington, DC
  Chief Medical Officer
  The Follicular Lymphoma Foundation
  London, United Kingdom
  
  Advisory Committee: Janssen Biotech Inc; Speakers Bureau: Acrotech Biopharma.
  
  John Strickler, MD
  Associate Professor
  Duke University
  Durham, North Carolina
  
  Advisory Committee: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, GlaxoSmithKline, Inivata, Natera Inc, Pfizer Inc, Seagen Inc, Silverback Therapeutics, Takeda Pharmaceuticals USA Inc, Viatris; Consulting Agreements: Bayer HealthCare Pharmaceuticals, Pionyr Immunotherapeutics, Seagen Inc, Zentalis Pharmaceuticals; Contracted Research: AbbVie Inc, Amgen Inc, AStar D3, Bayer HealthCare Pharmaceuticals, Curegenix, Daiichi Sankyo Inc, Erasca, Genentech, a member of the Roche Group, Gossamer Bio, Lilly, Nektar, Sanofi, Seagen Inc, Silverback Therapeutics; Data and Safety Monitoring Board/Committee: AbbVie Inc, Pionyr Immunotherapeutics.
  
  Saad Zafar Usmani, MD, MBA
  Chief of Myeloma Service
  Memorial Sloan Kettering Cancer Center
  New York, New York
  
  Consulting Agreements: AbbVie Inc, Amgen Inc, Bristol Myers Squibb, Celgene Corporation, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Janssen Biotech Inc, Oncopeptides, Sanofi, Seagen Inc, Secura Bio, SkylineDX, Takeda Pharmaceuticals USA Inc, TeneoBio; Contracted Research: Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Bristol Myers Squibb, Celgene Corporation, GlaxoSmithKline, Janssen Biotech Inc, Merck, Pharmacyclics LLC, an AbbVie Company, Sanofi, Seagen Inc, SkylineDX, Takeda Pharmaceuticals USA Inc; Speakers Bureau: Amgen Inc, Bristol Myers Squibb, Janssen Biotech Inc, Sanofi.
  
  Shannon N Westin, MD, MPH
  Professor
  Director, Early Drug Development
  Department of Gynecologic Oncology and Reproductive Medicine
  The University of Texas MD Anderson Cancer Center
  Houston, Texas
  
  Consulting Agreements: Agenus Inc, AstraZeneca Pharmaceuticals LP, Clovis Oncology, Eisai Inc, EQRx, Genentech, a member of the Roche Group, GlaxoSmithKline, ImmunoGen Inc, Lilly, Merck, Mereo BioPharma, Mersana Therapeutics Inc, NGM Bio, Nuvectis Pharma Inc, Seagen Inc, Vincerx Pharma, Zentalis Pharmaceuticals; Contracted Research: AstraZeneca Pharmaceuticals LP, Avenge Bio, Bio-Path Holdings, Clovis Oncology,Genentech, a member of the Roche Group, GlaxoSmithKline, Mereo BioPharma, OncXerna Therapeutics Inc, Zentalis Pharmaceuticals.
  
  Evan Y Yu, MD
  Professor of Medicine
  Division of Oncology, Department of Medicine
  University of Washington School of Medicine
  Member, Clinical Research Division
  Fred Hutchinson Cancer Research Center
  Medical Director, Clinical Research Services
  Fred Hutchinson Cancer Research Consortium
  Seattle, Washington
  
  Advisory Committee: Advanced Accelerator Applications, Bayer HealthCare Pharmaceuticals, Janssen Biotech Inc, Merck, Oncternal Therapeutics; Consulting Agreements: Exelixis Inc, Merck; Contracted Research: Bayer HealthCare Pharmaceuticals, Blue Earth Diagnostics, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Lantheus, Merck, Seagen Inc, Taiho Oncology Inc.
  
  MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  These activities are supported by educational grants from ADC Therapeutics, Astellas and Seagen Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol Myers Squibb, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Incyte Corporation, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Karyopharm Therapeutics, Lilly, Merck, Natera Inc, Novartis, Regeneron Pharmaceuticals Inc, and Seagen Inc.
  
  Release date: November 2022
  Expiration date: November 2023